Takeda: Carcinoma, Non-Small-Cell Lung trials

The registry lists 29 Carcinoma, Non-Small-Cell Lung studies with Takeda as lead sponsor. 1 are open to participants now and 11 have results posted.

Phase 1 9Phase 2 13Phase 3 3No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Survey of Brigatinib Used To Treat People With Non-Small Cell Lung CancerRecruitingNCT05100069
• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTerminatedNCT05070247Phase 1/2Results posted
• A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersCompletedNCT04879849Phase 1Results posted
• A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic CancerTerminatedNCT04844073Phase 1/2Results posted
• Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT04051827Phase 1Results posted
• A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung CancerActive, not recruitingNCT03807778Phase 1Results posted
• Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03410108Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid TumorsCompletedNCT03261947Phase 2Results posted
• ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3Results posted
• Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02393209Phase 1/2Results posted
• A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02094573Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)CompletedNCT01449461Phase 1/2Results posted
• A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETYActive, not recruitingNCT05735327
• A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)Active, not recruitingNCT05721950
• A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 InsertionCompletedNCT05419700
• A Chart Review Study of Adults With Advanced NSCLCCompletedNCT05207423
• A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)CompletedNCT04887519
• A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South KoreaCompletedNCT04592523
• A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788WithdrawnNCT04576208Phase 2
• An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion MutationsApproved for marketingNCT04535557
• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsCompletedNCT04129502Phase 3
• An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT02784158
• A Study of TAK-788 in Adults With Non-Small Cell Lung CancerActive, not recruitingNCT02716116Phase 1/2
• Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02629848Phase 3
• Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior TherapyCompletedNCT00343720Phase 2
• A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung CancerTerminatedNCT00283634Phase 2
• VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC FeaturesTerminatedNCT00117351Phase 2
• Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTerminatedNCT00064636Phase 1
• Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00051974Phase 2